RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027

American Journal of Ophthalmology

Volumn 150, Issue 1, 2010, Pages

  Kaiser, Peter K ^a   Symons, R C Andrew ^b   Shah, Syed Mahmood ^b   Quinlan, Edward J ^b   Tabandeh, Homayoun ^b   Do, Diana V ^b   Reisen, Gail ^c   Lockridge, Jennifer A ^c   Short, Brian ^d   Guerciolini, Roberto ^c   Nguyen, Quan Dong ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Sirna Therapeutics Inc   (United States)

^d ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN; PEGAPTANIB; SIRNA 027; TRIAMCINOLONE; VASCULOTROPIN RECEPTOR 1;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISCOMFORT; EYE EXAMINATION; EYE IRRITATION; EYE PAIN; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINOPEXY; RNA INTERFERENCE; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 77953909544     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.02.006     Document Type: Article

References (14)

1. Chopdar A., Chakravarthy U., and Verma D. Age related macular degeneration. BMJ 326 7387 (2003) 485-488
2. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
3. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39 5 (2006) 469-478
4. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 5 (2001) 575-583
5. Shen J., Samul R., Silva R.L., et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13 3 (2006) 225-234
6. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 2 (2002) 199-213
7. Tuschl T., and Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2 3 (2002) 158-167
8. Hutvagner G., and Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297 5589 (2002) 2056-2060
9. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., and Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110 5 (2002) 563-574
10. Tatlipinar S., Shah S.M., Campochiaro P.A., and Nguyen Q.D. Intraobserver repeatability of automated versus adjusted optical coherence tomography measurements in patients with neovascular age-related macular degeneration. Ophthalmologica 221 4 (2007) 227-232
11. Flores-Aguilar M., Besen G., Vuong C., et al. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis 175 6 (1997) 1308-1316
12. Monteith D.K., and Levin A.A. Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 27 1 (1999) 8-13
13. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 27 (2004) 2805-2816
14. Kleinman M.E., Yamada K., Takeda A., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 7187 (2008) 591-597